Junjie Xiong

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Ke Cheng · 5 shared papers, 2023–2026 · strength 0.89
   • Paper Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment fo… DOI 10.1136/bmjopen-2024-084274↗
   • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
   • Paper A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreat… DOI 10.1093/oncolo/oyac146↗
2. Dan Cao · 4 shared papers, 2023–2026 · strength 0.75
   • Paper Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment fo… DOI 10.1136/bmjopen-2024-084274↗
   • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
   • Paper A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreat… DOI 10.1093/oncolo/oyac146↗
3. Chenyan Zhang · 3 shared papers, 2024–2026 · strength 0.56
   • Paper Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment fo… DOI 10.1136/bmjopen-2024-084274↗
   • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
4. Chen Chang · 3 shared papers, 2023–2026 · strength 0.54
   • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
   • Paper A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreat… DOI 10.1093/oncolo/oyac146↗
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
5. Yi Cheng · 3 shared papers, 2024–2026 · strength 0.51
   • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
   • Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8↗
6. Bole Tian · 3 shared papers, 2021–2026 · strength 0.50
   • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
   • Paper Clinical characteristics and treatment analysis of pancreatic acinar cell carcinoma: A single institutional comparison … DOI 10.1016/j.suronc.2021.101528↗
   • Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8↗
7. Zixing Huang · 3 shared papers, 2023–2026 · strength 0.50
   • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
   • Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1↗
8. Wanrui Lv · 3 shared papers, 2023–2024 · strength 0.48
   • Paper A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreat… DOI 10.1093/oncolo/oyac146↗
   • Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8↗
   • Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1↗
9. Rui Wang · 3 shared papers, 2023–2025 · strength 0.46
   • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
   • Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8↗
   • Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1↗
10. Nengwen Ke · 4 shared papers, 2016–2022 · strength 0.36
    • Paper The expression of m6A regulators correlated with the immune microenvironment plays an important role in the prognosis o… DOI 10.21037/gs-21-859↗
    • Paper A case-matched comparison study of total pancreatectomy versus pancreaticoduodenectomy for patients with pancreatic duc… DOI 10.1016/j.ijsu.2017.10.065↗
    • Paper MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated auto… DOI 10.18632/oncotarget.22494↗
11. Xiaorui Zhu · 2 shared papers, 2025–2026 · strength 0.36
    • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
12. Qingqing Leng · 2 shared papers, 2025–2026 · strength 0.36
    • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
13. Wanting Hou · 2 shared papers, 2025–2026 · strength 0.36
    • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
14. Huimin Lü · 3 shared papers, 2017–2021 · strength 0.33
    • Paper Clinical characteristics and treatment analysis of pancreatic acinar cell carcinoma: A single institutional comparison … DOI 10.1016/j.suronc.2021.101528↗
    • Paper The oncological safety in minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a … DOI 10.1038/s41598-018-37617-0↗
    • Paper Deregulated expression of miR-107 inhibits metastasis of PDAC through inhibition PI3K/Akt signaling via caveolin-1 and … DOI 10.1016/j.yexcr.2017.10.033↗
15. Xiaoying Li · 2 shared papers, 2024–2025 · strength 0.32
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
    • Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8↗
16. Chengjian Zhao · 2 shared papers, 2023–2025 · strength 0.31
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
    • Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1↗
17. Xubao Liu · 3 shared papers, 2016–2022 · strength 0.29
    • Paper The expression of m6A regulators correlated with the immune microenvironment plays an important role in the prognosis o… DOI 10.21037/gs-21-859↗
    • Paper A case-matched comparison study of total pancreatectomy versus pancreaticoduodenectomy for patients with pancreatic duc… DOI 10.1016/j.ijsu.2017.10.065↗
    • Paper dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinom… DOI 10.1097/md.0000000000002936↗
18. Chunlu Tan · 3 shared papers, 2016–2022 · strength 0.29
    • Paper The expression of m6A regulators correlated with the immune microenvironment plays an important role in the prognosis o… DOI 10.21037/gs-21-859↗
    • Paper Deregulated expression of miR-107 inhibits metastasis of PDAC through inhibition PI3K/Akt signaling via caveolin-1 and … DOI 10.1016/j.yexcr.2017.10.033↗
    • Paper dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinom… DOI 10.1097/md.0000000000002936↗
19. Weiming Hu · 3 shared papers, 2017–2019 · strength 0.24
    • Paper The oncological safety in minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a … DOI 10.1038/s41598-018-37617-0↗
    • Paper MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated auto… DOI 10.18632/oncotarget.22494↗
    • Paper Deregulated expression of miR-107 inhibits metastasis of PDAC through inhibition PI3K/Akt signaling via caveolin-1 and … DOI 10.1016/j.yexcr.2017.10.033↗
20. Ailin Wei · 3 shared papers, 2017 · strength 0.21
    • Paper A case-matched comparison study of total pancreatectomy versus pancreaticoduodenectomy for patients with pancreatic duc… DOI 10.1016/j.ijsu.2017.10.065↗
    • Paper MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated auto… DOI 10.18632/oncotarget.22494↗
    • Paper Deregulated expression of miR-107 inhibits metastasis of PDAC through inhibition PI3K/Akt signaling via caveolin-1 and … DOI 10.1016/j.yexcr.2017.10.033↗
21. Yi Zhang · 1 shared paper, 2026 · strength 0.19
    • Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
22. Yutong Yao · 1 shared paper, 2022 · strength 0.16
    • Paper The expression of m6A regulators correlated with the immune microenvironment plays an important role in the prognosis o… DOI 10.21037/gs-21-859↗
23. Yonghua Chen · 1 shared paper, 2022 · strength 0.16
    • Paper The expression of m6A regulators correlated with the immune microenvironment plays an important role in the prognosis o… DOI 10.21037/gs-21-859↗
24. Yi Zhang · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
25. Huanji Xu · 1 shared paper, 2025 · strength 0.16
    • Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.